To further extend the clinical potential of our results, we reasoned that the role of PARP1 in the RSR of neoR-CRC-SCs could make these cells vulnerable to the inhibition of other fork remodeling/stabilizing players, focusing on the druggable players MRE11 and RAD51 [52]. The gene discussed is MRE11; the disease is colorectal carcinoma.